Table 10.

Number of participants reporting adverse events in each rs4680 genotype group.

Item	GG
Opioids	Group M (n = 29)				Group O (n = 30)
Adverse event	Grade 1; n (%)	Grade 2; n (%)	Grade 3; n (%)	Grade 4; n (%)	Grade 1; n (%)	Grade 2; n (%)	Grade 3; n (%)	Grade 4; n (%)
Somnolence	7 (24.1)	5 (17.2)	0 (0.0)	0 (0.0)	11 (36.7)	0 (0.0)	0 (0.0)	0 (0.0)
Nausea	6 (20.7)	2 (6.9)	0 (0.0)	0 (0.0)	5 (16.7)	3 (10.0)	0 (0.0)	0 (0.0)
Vomiting	3 (10.3)	2 (6.9)	0 (0.0)	0 (0.0)	5 (16.7)	1 (3.3)	0 (0.0)	0 (0.0)
Constipation	7 (24.1)	6 (20.7)	0 (0.0)	0 (0.0)	5 (16.7)	5 (16.7)	0 (0.0)	0 (0.0)
Delirium	1 (3.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Others	3 (10.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Item	Non-GG
Opioids	Group M (n = 41)				Group O (n = 39)
Adverse event	Grade 1; n (%)	Grade 2; n (%)	Grade 3; n (%)	Grade 4; n (%)	Grade 1; n (%)	Grade 2; n (%)	Grade 3; n (%)	Grade 4; n (%)
Somnolence	17 (41.5)	1 (2.4)	0 (0.0)	0 (0.0)	12 (30.8)	1 (2.6)	0 (0.0)	0 (0.0)
Nausea	8 (19.5)	4 (9.8)	0 (0.0)	0 (0.0)	9 (23.1)	1 (2.6)	0 (0.0)	0 (0.0)
Vomiting	5 (12.2)	3 (7.3)	0 (0.0)	0 (0.0)	5 (12.8)	0 (0.0)	0 (0.0)	0 (0.0)
Constipation	9 (22.0)	11 (26.8)	0 (0.0)	0 (0.0)	13 (33.3)	6 (15.4)	0 (0.0)	0 (0.0)
Delirium	2 (4.9)	0 (0.0)	0 (0.0)	0 (0.0)	2 (5.1)	1 (2.6)	0 (0.0)	0 (0.0)
Others	1 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Abbreviations: group M, morphine-treated group; group O, oxycodone-treated group.